Shire Buys Renal Disease Biotech Fibrotech, Aims Big At Neuroscience
This article was originally published in The Pink Sheet Daily
Executive Summary
The Ireland-based specialty pharma, itself created by acquisition, generated strong top-line revenue growth and higher profits in the first quarter, helped by full consolidation of ViroPharma. Shire also underscored its aim for future innovation by buying renal disease biotech Fibrotech and predicting its neuroscience operations will double sales by 2020.
You may also be interested in...
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.